What is CoRegen?
CoRegen Diagnostics is a prominent player in the biotechnology and precision medicine landscape, dedicated to the development of advanced molecular diagnostic tests. These tests are designed to empower oncologists by providing critical genetic insights from tumor samples, thereby facilitating more precise and effective treatment decisions for cancer patients. By analyzing the unique genetic makeup of a patient's cancer, CoRegen's solutions aim to optimize therapeutic strategies, moving towards a more personalized approach in cancer care.
How much funding has CoRegen raised?
CoRegen has raised a total of $106.5M across 2 funding rounds:
Other Financing Round
$93M
Private Equity
$13.5M
Other Financing Round (2025): $93M, investors not publicly disclosed
Private Equity (2026): $13.5M, investors not publicly disclosed
What's next for CoRegen?
The substantial enterprise-level funding CoRegen has attracted positions the company for accelerated growth and expanded market penetration. This capital infusion is expected to fuel further research and development into novel diagnostic technologies, potentially broadening the scope of cancers addressed and enhancing the predictive capabilities of their tests. Strategic partnerships and further commercialization efforts are likely next steps as CoRegen aims to solidify its leadership in precision oncology diagnostics, leveraging its recent strategic investment to drive innovation and clinical adoption.
See full CoRegen company page
